Study of S-1 Plus DC-CIK for Patients With Advanced Gastric Cancer
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1 based chemotherapy for advanced gastric cancer.
Gastric Cancer
BIOLOGICAL: DC-CIK|DRUG: S-1|DRUG: Cisplatin
Progression free survival（PFS）, 4 years
Overall survival, 4 years|Response rate, Every 6 weeks|Adverse Events, Every 3 weeks|Quality of life, Evaluation of quality of life will be performed every 2 cycles (6 weeks) from baseline to the end of treatment., 6 weeks
The purpose of this study is to evaluate the antitumor effect and safety of clinical effectiveness dendritic cell activated Cytokine induced killer treatment (DC-CIK) plus S-1 based chemotherapy for advanced gastric cancer.